UnitedHealth Group is entering 2026 under intensifying scrutiny — and increasingly divided Wall Street opinion.
Shares of UnitedHealth Group (NYSE: UNH) have come under pressure after analysts trimmed price targets and regulatory risks resurfaced around Medicare Advantage practices. The healthcare giant, valued at roughly $265.66 billion, now finds itself at a turning point: balancing a $439 billion revenue outlook against legal, reimbursement, and valuation headwinds.
Price targets cut as fair value drops 7%
Simply Wall St trimmed its fair value estimate for UnitedHealth from $392.24 to $364.63, a reduction of about 7%. That shift aligns with a broader split in analyst views, where lower targets from several firms sit alongside a smaller group of higher calls tied to execution on a turnaround plan.
A wide group of firms — including Barclays, Bank of America, Leerink, RBC Capital, Morgan Stanley, UBS, Wells Fargo, Truist, JPMorgan, and Mizuho — have cut price targets by $20 to $80, signaling greater caution around valuation and execution risk.
Wall Street split: targets up to $444 on turnaround confidence
Not all analysts are retreating. Bernstein lifted its price target to $444 from $440, pointing to a potential turnaround in government managed care and highlighting Medicare Advantage and Medicaid as areas it views as attractive.
Evercore ISI started coverage with a $400 price target and framed UnitedHealth as an execution story, expressing confidence in the company’s turnaround plan over the next few years.
Cantor Fitzgerald described the proposed Great Healthcare Plan as a favorable outcome for insurers and characterized the UnitedHealth selloff as overdone, suggesting a disconnect between price and fundamentals.
Mizuho has discussed upcoming Medicare Advantage 2027 rates as a potential catalyst. Meanwhile, Piper Sandler reiterated an Overweight rating and maintained a $390 price target, citing confidence in Optum Health despite an operating income miss in 2025.
Big numbers, mixed signals
UnitedHealth remains one of the largest healthcare companies in the world, and the numbers are still massive. The company reported revenue (TTM) of $447.57 billion and is guiding for 2026 revenue above $439.0 billion, with earnings from operations greater than $24.0 billion and earnings per share above $17.10.
In the fourth quarter of 2025, UnitedHealth’s results were steady but not flawless: earnings per share came in at $2.11, while revenue was $113.2 billion versus $113.73 billion expected.
DOJ probe and Senate report intensify scrutiny
Regulatory and legal risk is now firmly embedded in the UnitedHealth narrative. A Senate committee report, covered by The Wall Street Journal, alleges UnitedHealth used aggressive tactics to boost diagnoses for Medicare Advantage members and highlights ongoing civil and criminal Justice Department probes.
Separate reporting has also added to scrutiny of sector business practices, keeping the risk premium elevated for managed-care names. Analysts including Deutsche Bank and BofA have flagged the 2027 CMS rate notice and related commentary as a significant negative for managed care, with Cantor Fitzgerald suggesting a quick recovery after the CMS call is unlikely.
Dividend remains in focus
Despite the turbulence, UnitedHealth continues to return cash to shareholders. The company declared a quarterly cash dividend of $2.21 per share, set to be paid on March 17, 2026, to shareholders of record as of March 9, 2026.
Accounting leadership change and an Optum UK headline
UnitedHealth appointed Dennis Stankiewicz as chief accounting officer, effective Monday. Stankiewicz, age 48, will continue to serve as corporate controller, a position he has held since April 17, 2023. In connection with the new role, the company approved an annual base salary of $550,000 and an initial annual cash bonus target set at 85% of base salary, alongside annual and long-term stock-based awards consistent with his responsibilities.
Tom Roos, who has served as chief accounting officer since August 2015, will transition to the role of chief financial officer at Optum Insight, effective Monday.
Separately, Sky News has reported that TPG is close to acquiring Optum’s UK operation from UnitedHealth in a deal worth more than £1 billion, a potential shift that could alter the group’s domestic and international mix.
Valuation debate: bargain or risk discount?
At the center of the debate is whether the stock is being discounted too aggressively for regulatory uncertainty. With guidance calling for 2026 EPS above $17.10 and operating earnings above $24.0 billion, the company is giving investors clear reference points — but the DOJ probe and reimbursement uncertainty into 2027 remain the key overhangs shaping the next leg for the shares.
For investors, 2026 becomes a proving ground. If UnitedHealth executes against its outlook and stabilizes its government book, the stock can rebuild confidence. If regulatory or rate pressure deepens, the discount may persist. UnitedHealth is no longer priced for perfection — and that tension defines the crossroads.
